Outcome predictors of burkitt{u2019}s lymphoma in children and adolescents : A single- institution experience / Esraa Maged Mohammad ; Supervised Hanafy Ahmed Hafez , Riham Abdelaziz Khedr , Eman Naguib Khorshed
Material type:
- العوامل المتنبئة بالإستجابة فى سرطان الغدد الليمفاوية فى الأطفال و المراهقين : تجربة مؤسسة واحدة [Added title page title]
- Issued also as CD
Item type | Current library | Home library | Call number | Copy number | Status | Barcode | |
---|---|---|---|---|---|---|---|
![]() |
قاعة الرسائل الجامعية - الدور الاول | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.19.05.M.Sc.2019.Es.O (Browse shelf(Opens below)) | Not for loan | 01010110080482000 | ||
![]() |
مخـــزن الرســائل الجـــامعية - البدروم | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.19.05.M.Sc.2019.Es.O (Browse shelf(Opens below)) | 80482.CD | Not for loan | 01020110080482000 |
Browsing المكتبة المركزبة الجديدة - جامعة القاهرة shelves Close shelf browser (Hides shelf browser)
Thesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Pediatric Oncology
Background/objective; The outcome of childhood Burkitt{u2019}s lymphoma (BL) has improved steadily over the past decades through the use of intensive sequential multi-agent chemotherapy regimens. This study objective was to assess the outcome predictors of BL in children and adolescents. Methods: A retrospective study included all patients 18 years old or younger diagnosed with BL and treated according to the modified LMB 96 protocol at National Cancer Institute, Cairo university from January 2012 to December 2016 and their follow up till December 2018. Results: A total of 170 patients were diagnosed with BL, with median age of 5 years old. Abdomen was the most common 1ry site (90.0%). Bone marrow involvement was encountered in 7 patients (4%) and 10 (6%) had central nervous system (CNS) disease at presentation. From the whole study cohort, 7 patients (4.1%) were treated as group A, 130 (76.5%) as group B, and 27 (15.9%) patients as group C. The 5 years overall survival (OS) and event free survival (EFS) were 82.9% and 82.8% respectively for the whole group. OS and EFS were 100%, 87.2% and 57.7% for group A, B and C respectively (P<0.001). Significant survival difference due to BM involvement and /or CNS involvement, 50% for (BM+) vs 84.2% for (BM-) (P= 0.026) and 40% for (CNS+) vs 85.8% for (CNS-) (P<0.001). Early initiation of induction cycle in a period {u2264} 10 days of CVP start was associated with better outcome 87.3% vs 68.6% for delayed group >10 days (P=0.020). A total of 39 deaths were reported, about 50% of them were defined as early deaths before 2nd induction and 11 patients died due to disease progression
Issued also as CD
There are no comments on this title.